2016
High-dose methotrexate-based chemotherapy as treatment for histiocytic sarcoma of the central nervous system
Curry RC, Faivre G, Akkari L, Joyce JA, Lin O, Rosenblum M, Diamond EL, Fisher R, Omuro A. High-dose methotrexate-based chemotherapy as treatment for histiocytic sarcoma of the central nervous system. Leukemia & Lymphoma 2016, 57: 1961-1964. PMID: 26727454, DOI: 10.3109/10428194.2015.1120867.Peer-Reviewed Original Research
2015
Patterns of response and relapse of primary central nervous system lymphomas (PCNSL) following first line of high-dose methotrexate-based chemotherapy (hdMTX): Analysis of a prospective ANOCEF randomized phase II trial.
Tabouret E, Houillier C, Martin-Duverneuil N, Blonski M, Soussain C, Ghesquieres H, Houot R, Delwail V, Soubeyran P, Gressin R, Gyan E, Chinot O, Taillandier L, Tanguy M, Omuro A, Hoang-Xuan K. Patterns of response and relapse of primary central nervous system lymphomas (PCNSL) following first line of high-dose methotrexate-based chemotherapy (hdMTX): Analysis of a prospective ANOCEF randomized phase II trial. Journal Of Clinical Oncology 2015, 33: 2035-2035. DOI: 10.1200/jco.2015.33.15_suppl.2035.Peer-Reviewed Original Research
2012
Primary Central Nervous System Lymphomas
Graber J, Omuro A. Primary Central Nervous System Lymphomas. 2012, 125-133. DOI: 10.1002/9781118321478.ch12.Peer-Reviewed Original ResearchPrimary CNS lymphomaHigh-dose methotrexate-based chemotherapyPrimary central nervous system lymphomaCentral nervous system lymphomaMethotrexate-based chemotherapyNervous system lymphomaNon-Hodgkin lymphomaLong-term survivalCNS lymphomaOptimal regimenImmunosuppressed patientsSystem lymphomaAppropriate therapyDisease relapseEarly suspicionDiagnostic accuracyLymphomaInappropriate interventionsPatientsImmunocompetentRegimenChemotherapyRelapseRadiotherapyNeurotoxicity
2011
Primary central nervous system lymphoma
Graber JJ, Omuro A. Primary central nervous system lymphoma. Current Opinion In Neurology 2011, 24: 633-640. PMID: 21968551, DOI: 10.1097/wco.0b013e32834cbdef.Peer-Reviewed Original ResearchConceptsPrimary central nervous system lymphomaCentral nervous system lymphomaReduced-dose radiotherapyProgression-free survivalNervous system lymphomaNeurotoxicity ratesSystem lymphomaChemotherapy-only treatmentHigh-dose methotrexateStem cell rescueWhole brain radiotherapyHigh-dose chemotherapyPhase II studyWorse cognitive outcomesChemotherapy regimenSalvage treatmentII studyOlder patientsOverall survivalBrain damageChemotherapyRadiotherapyAdditional neurotoxicityRoutine practiceNeuropsychological evaluation
2007
Molecular genetic markers as predictors of response to chemotherapy in gliomas
Idbaih A, Omuro A, Ducray F, Hoang-Xuan K. Molecular genetic markers as predictors of response to chemotherapy in gliomas. Current Opinion In Oncology 2007, 19: 606-611. PMID: 17906460, DOI: 10.1097/cco.0b013e3282f075f3.Peer-Reviewed Original ResearchConceptsAnaplastic oligodendroglial tumorsLow-grade gliomasProspective trialMGMT statusOligodendroglial tumorsIndependent favorable prognostic factorFavorable prognostic factorRelevant prognostic markerPredictors of responsePromoter methylationTreatment of gliomaPredictor of chemosensitivityMGMT promoter methylationObjective responsePrognostic factorsRetrospective studyPrognostic markerSuch tumorsTreatment decisionsChromosome 1p/19q codeletionMGMT inactivationPredictive valueChemotherapyGliomasLow expression
2006
Chemotherapy for primary central nervous system lymphoma.
Omuro AM, Abrey LE. Chemotherapy for primary central nervous system lymphoma. Neurosurgical FOCUS 2006, 21: e12. PMID: 17134114, DOI: 10.3171/foc.2006.21.5.13.Peer-Reviewed Original ResearchConceptsPrimary central nervous system lymphomaCentral nervous system lymphomaHigh-dose methotrexateUse of chemotherapyNervous system lymphomaElderly patientsSystem lymphomaSuch elderly patientsMainstay of treatmentToxic regimensChemotherapy regimensCorticosteroid agentsYounger patientsPatient ageRelapse rateRandomized trialsDifferent regimensOptimal treatmentRecent trialsTreatment paradigmHigh riskChemotherapyEffective drugsSingle agentRegimens